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Abstract
Background—Children with sickle cell disease (SCD) are susceptible to recurrent infections,
which are often life threatening and necessitate frequent vaccinations. Given the altered baseline
immunity and proinflammatory state associated with SCD, we sought to determine the relative
safety and efficacy of vaccination in transgenic SCD mice.
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Methods—Eight week-old SCD mice were vaccinated with ovalbumin (OVA) and aluminum
hydroxide weekly for three weeks by the intraperitoneal (IP) or intramuscular (IM) route. One
week after the third vaccination, serum cytokines/chemokines, immunoglobulins, and
bronchoalveolar lavage (BAL) fluid cytokines were measured.
Results—Only SCD mice were prone to mortality associated with vaccination as 40% of the
animals died after the IP vaccinations and 50% died after the IM vaccinations. Serum IgG2b and
IgM were significantly lower in SCD than C57Bl/6 mice after vaccination, but OVA-specific IgE
was significantly higher. Serum interleukin 1 alpha (IL-1α), IL-2, IL-5, macrophage inflammatory
protein 1 alpha (MIP-1α), and granulocyte macrophage-colony stimulating factor (GM-CSF) were
significantly lower in SCD mice than C57Bl/6 mice after vaccination, whereas BAL fluid IL-1β
and IL-6 were elevated.
Conclusions—Mice with SCD appear to have a dysregulated immune response to vaccination.
Thus, the relative safety and immunogenicity of vaccination should be studied in greater detail in
the context of SCD.
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INTRODUCTION
Children suffering from sickle cell disease (SCD) are prone to frequent and severe infections
that can lead to premature death if prompt antibiotic treatment is not administered. One of
the most common infections in children with SCD is caused by Streptococcus pneumoniae,
which often manifests as pneumonia and can lead to septicemia if the bacterium becomes
invasive. The incidence of invasive S. pneumoniae infection in individuals with SCD is
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between 30–600 fold higher (depending on age) than what is observed in the general
population (1). As a consequence, children with SCD typically adhere to strict vaccination
schedules which often include more frequent booster shots than children without SCD. The
introduction of pneumococcal vaccines has reduced the incidence of mortality associated
with S. pneumoniae infection in children with SCD by 80–90% (2, 3); however, infection in
vaccinees has nevertheless been reported in this population (4). Vaccination against both S.
pneumoniae and Influenza A virus appear to result in low antigen-specific IgG and IgM
antibody titers (5, 6), the latter of which is likely a function of a reduced number of IgM
producing B-cells (7, 8). Furthermore, a recent study has shown an association between
chronic transfusion of children with SCD and a lack of a protective post-vaccination
antibody response to influenza A (9). Taken together, these findings bring into question the
relative immunogenicity of vaccination in children with SCD when compared to control
subjects and indicate that hypo-responsiveness to vaccine antigens may not be uncommon.
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The phase one safety evaluations of vaccines are usually tested in the general population but
are not tested in individuals with uncommon diseases such as SCD. The recently developed
intranasal influenza vaccine (FluMist, MedImmune, Gaithersburg, MD) is one such example
and, consequently, administration of this vaccine to SCD patients is not recommended by
the CDC. Even when a vaccine is routinely administered as part of the standard vaccination
schedule, such as is the case with the trivalent inactivated influenza (TIV) vaccine,
controversy may arise pertaining to its safety in people with uncommon diseases. Indeed,
recent retrospective studies using the vaccine safety datalink project have indicated that the
TIV vaccine is not associated with hospitalization in children or adults with SCD (10, 11);
however, a previous report by this group had shown that people with SCD had more
frequent fever or pain episodes resulting in an inpatient visit within two weeks of influenza
vaccination than control subjects (12). To our knowledge, no published prospective studies
have been conducted in humans or mice to definitively determine if vaccination is associated
with adverse effects in SCD.
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Very little work has been conducted in transgenic SCD mice to study the effects of
experimental treatment on basic outcomes that cannot be tested in humans. One of the few
papers to do so demonstrated that NKT-cells are an important source of pulmonary
dysfunction at baseline in NY1DD SCD mice (13). Another report used intraperitoneal (IP)
injection of lipopolysaccharide (LPS) into the “Berkeley” (Berk) transgenic SCD mouse
strain to determine the effects of systemic challenge with an inflammatory agent on markers
of disease (14). Many of these mice died shortly after injection and the survivors exhibited
negative respiratory outcomes and had increased inflammatory markers. In another study,
experimental asthma was induced in SCD mice by subcutaneous (SC) implantation of
ovalbumin (OVA), followed by OVA aerosol challenge (15). Mortality of SCD mice was
associated with SC implantation of OVA, and marked increases in IgE was observed. A
follow-up study by the same group also demonstrated increases in bronchoalveolar lavage
(BAL) cytokines (including IL-1β and IL-6) after the induction of asthma in SCD mice (16).
Taken together, these findings indicate that SCD results in exaggerated inflammatory
responses in reaction to antigenic stimuli.
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There appears to be a dichotomy in SCD between hypo-responsiveness to some antigens and
an overzealous inflammatory response to others. Our original goal was to study asthma in a
murine model of SCD using our previously published IP OVA/Alum vaccination/
sensitization protocol (17). However, upon experiencing approximately 50% mortality with
sensitization alone in multiple experiments, we shifted focus to understand how transgenic
SCD mice respond to vaccination. Herein, we describe changes in systemic and pulmonary
cytokines, serum antibodies, and antigen-specific IgE responses in SCD mice surviving
vaccination as compared with wild-type and hemizygous mice. Implications for infection
and vaccination in children with SCD are discussed.

RESULTS
Vaccination-Induced Mortality
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IP vaccination of SCD mice with the protein antigen OVA and adjuvant alum resulted in
significant mortality (40%) when compared to either C57Bl/6 or hemizygous (no deaths in
either group; p<0.05; Figure 1). This effect occurred with increasing frequency at each
additional IP injection. In order to validate that the route of inoculation was not the major
factor of SCD mouse mortality, additional mice were inoculated with OVA/alum via the IM
route. Again, only SCD mice died after the injections (50%), which was significantly
different from C57Bl/6 and hemizygous mice. Interestingly, the kinetics of mortality were
different between the two routes of inoculation, with IP resulting in the greatest mortality
after the third vaccination and IM only resulting in mortality after one vaccination.
Antibody Responses
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Concentrations of post-vaccination serum immunoglobulin class and sub-classes were
measured one week after the third vaccination using a Luminex assay. When compared to
C57Bl/6 mice, SCD mice exhibited significantly lower serum concentrations of IgG2b
(Figure 2A). Serum concentrations of IgM were also significantly reduced in SCD mice. No
differences were observed in any post-vaccination Ig class/sub-class between SCD and
hemizygous mice. When comparing pre- versus post- vaccination serum antibody levels,
dramatically higher fold-change increases were observed for IgG2b in C57Bl/6 mice than in
SCD mice, indicating that the lower level of this Ig sub-class post-vaccination is attributable
to an inability of SCD mice to produce it in response to vaccination (Figure 2B). No
difference in the fold-change of IgM concentrations in the pre- versus post-vaccination
samples was observed among the groups (Figure 2B), which is likely attributed to the
previously reported reduction of IgM at baseline in SCD mice (8). When compared with
C57Bl/6 mice, SCD mice exhibited dramatically increased OVA-specific IgE titers after
vaccination (Figure 2C), indicating that SCD mice may be more prone to allergic
sensitization than C57Bl/6 mice. No difference was observed in OVA-specific IgE titers
when SCD and hemizygous mice were compared.
Cytokine/Chemokine Responses
Concentrations of post-vaccination serum cytokines and chemokines were measured one
week after the third vaccination using a Luminex assay. When compared to C57Bl/6 mice,
SCD mice had lower serum concentrations of the cytokines IL-1α, IL-2, and IL-5 (Figure
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3A). Reduced concentrations of serum chemokines MIP-1α and GM-CSF were also found.
No significant differences in the aforementioned cytokines/chemokines were measured
between SCD and hemizygous mice. When comparing pre- versus post-vaccination cytokine
levels, fold-change differences in IL-1α were not noticeably different among the groups
(Figure 3B), which is likely attributed to the previously reported reduction of this cytokine at
baseline in SCD mice (8). Dramatically higher pre- versus post-vaccination fold-change
increases were observed for both IL-2 and GM-CSF in C57Bl/6 mice than SCD mice,
indicating that the lower levels of these cytokines post-vaccination is attributed to an
inability of SCD mice to produce them in response to vaccination. Moreover, when preversus post-vaccination titers were compared, SCD mice exhibited reduced levels of
MIP-1α. This indicates that SCD has a severely dysregulated MIP-1α response after
vaccination.
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Several serum cytokines were significantly increased in response to vaccination in C57Bl/6
mice, but not in SCD or hemizygous mice (Figure 3C). These cytokines include IL-1β, IL-7,
IL-12(p70), and IL-17. These cytokines exhibited more variability within groups, thereby
contributing to a lack of significance when post-vaccination concentrations were compared.
However, SCD mice (and hemizygous) appear to have a reduced ability to produce these
cytokines in response to vaccination. Taken together, SCD mice that survive inoculation
appear to be hypo-responsive to vaccination, as demonstrated by their lack of cytokine
production in serum post-vaccination.
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In contrast to the hypo-responsiveness exhibited by SCD mice in the production of serum
cytokines after vaccination, cytokines in BAL fluid appeared to be higher in SCD mice
(Figure 4). BAL fluid IL-1β was not measurable in C57Bl/6 mice post-vaccination (MDL =
0.20 pg/ml) and was significantly higher in SCD mice when compared with either
hemizygous mice or C57Bl/6 mice. Similarly, IL-6 was elevated in the BAL fluid of SCD
mice when compared with C57Bl/6 mice (not measurable, MDL = 0.28 pg/ml) after
vaccination. No differences in post-vaccination BAL fluid IL-6 were observed between
hemizygous mice and SCD mice.

DISCUSSION
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Relative safety and immunogenicity are important features to consider when administering
vaccines, yet these two basic parameters are not well-understood in children with
uncommon diseases such as SCD. Death of SCD mice after injection of inflammatory agents
is a phenomenon that has been known for some time and is presumably associated with
heightened baseline inflammation. A previous study showed that IP inoculation with the
proinflammatory molecule LPS resulted in approximately 60% mortality of SCD mice,
whereas sham inoculation with saline had no effect (14). Protein antigens may also produce
mortality in SCD mice, as has been shown by SC implantation of OVA (15). Our findings of
approximately 40% mortality in SCD mice after IP OVA/alum injection and 50% mortality
after IM OVA/alum injection correlate with these previous reports. Thus, our model of
vaccination has clinical implications pertaining to possible adverse events associated with
vaccination of children with SCD.
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The gold standard of immunogenicity for most vaccines is elicitation of the production of
antigen-specific serum antibodies. As previously mentioned, SCD mice that survived
vaccination had significantly higher OVA-specific IgE antibody serum concentrations than
C57Bl/6 mice, indicating that these animals may be especially prone to allergic
sensitization. Conversely, these same mice were hypo-responsive in terms of IgG2b and
IgM production after vaccination. All groups of mice increased their IgM titers 4-fold in
response to vaccination, which indicates that differences in post-vaccination IgM
concentrations are due to low baseline production of this immunoglobulin. However, SCD
mice only induced a 4-fold increase in IgG2b after vaccination, whereas C57Bl/6 mice
increased serum concentrations more than 10-fold. The inability of SCD mice to induce
wild-type levels of IgG2b antibodies has potential clinical implications as murine IgG2b is
similar to human IgG3 (and to some degree IgG1) (18), with the ability to fix complement
and bind to protein antigens. It is crucially important for vaccines to induce these functions
for maximum efficacy. These findingsare also in line with the observation that children
living with SCD have diminished antibody responses to the hepatitis B vaccine (19). Taken
together, these findings have translational implications that should be investigated further in
children living with SCD.
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The ability of lymphocytes to become activated and proliferate in response to stimuli is
essential for vaccine immunogenicity. Cytokines such as IL-2, IL-7, and IL-12 are
responsible for allowing lymphocytes to mature/differentiate, proliferate, and generate
immunological memory. The reduced post-vaccination serum concentrations and apparent
inability of these cytokines to be sufficiently stimulated after vaccination indicate that
lymphocytes in SCD mice surviving vaccination may have sub-par effector and memory
functions. Furthermore, chemokines MIP-1α and GM-CSF, which are important for
stimulating (20) and mobilizing (21) antigen presenting cells (APCs) in response to antigen,
are not produced at wildtype levels by SCD mice following vaccination. In fact, MIP-1α
appears to be down-regulated in response to vaccination in SCD mice. This has serious
implications as MIP-1α is important for mobilization of DC precursors into the blood (22).
MIP-1α is also a ligand for CCR5, which has been shown to be important for protection
from pathogens such as influenza (23). Furthermore, it has been reported that there is a
higher proportion of SCD patients in Brazil that also have the CCR5D32 mutant allele when
compared to controls (24). Extrapolation of our results from the mouse model then indicates
that these individuals may mount suboptimal immune responses to vaccination which may
then leave them more susceptible to infection. SCD mice are also hypo-responsive to IL-17
production post-vaccination and this cytokine is important for clearance of mucosal bacterial
pathogens. Indeed, protection of mice from S. pneumoniae colonization appears to be IL-17dependent (25), which suggests that lack of IL-17 production in SCD mice may contribute to
their increased susceptibility to pneumococcal infection (26).
Mouse models of acute lung injury are associated with increased levels of TNF-α, IL-1β,
and IL-6 in BAL fluid. This milieu has been shown to increase the production of secretory
IgA in the lungs to help protect from infection when the natural barrier defenses are
weakened (27). SCD mice that survived vaccination had significantly elevated IL-1β and
IL-6 in their BAL fluid one week after the third vaccination when compared with C57Bl/6
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mice, indicating that lung injury associated with vaccination had occurred. Given the longelapsed time between inoculation and measurement of these cytokines, it would not be
surprising if they were in fact higher in concentration in the lung airways at earlier time
points. It would also not be surprising if TNF-α is elevated early on as well. A study of
acute lung injury in SCD mice also showed increased IL-6 in BAL fluid within hours of LPS
injection (14), which corroborates our findings. The finding of increased IL-1β in BAL fluid
of SCD mice that survived vaccination also has clinical implications, as this cytokine has
been associated with ischemic reperfusion injury in human SCD (28), which is also
associated with acute chest syndrome. Thus, therapeutics targeting IL-6 and IL-1β may help
to reduce pulmonary-related morbidity and mortality in people living with SCD.
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Vaccination-related death of SCD mice raises the question by what mechanism these
animals are dying. This study does not directly address this question, as all outcomes were
measured one week after the third vaccination only in animals that tolerated the OVA/alum
inoculation. However, we were able to determine that the SCD mice that tolerated IP
vaccination had similarly high levels of antigen-specific serum IgE as the hemizygous
controls, which were much higher than those found in C57Bl/6 mice. This raises the
possibility that the sensitive SCD mice may have had even higher IgE levels and died of
shock from a type I hypersensitivity reaction. Anecdotal support of this hypothesis comes
from the observation that all SCD mice that died after vaccination were found dead within
hours of OVA/alum injection. Furthermore, all but one SCD mouse died after the second or
third IP injection, indicating that the mice had to be first sensitized to OVA/alum before they
became susceptible to death from vaccination. Interestingly, susceptible SCD mice that were
inoculated by the IM route all died after the first vaccination, indicating that these mice did
not have to be sensitized to antigen to be susceptible to death associated with this route of
vaccination. It therefore seems likely that these animals died from an exaggerated
inflammatory response, possibly driven by the presence of the adjuvant alum. While we do
not know the cause of vaccination-related death of SCD mice, it is likely a combination of
multiple etiologies which may include both hypersensitivity reactions and exaggerated
inflammatory responses. Further work is needed in order to more definitively answer this
question.
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Many studies have shown that both humans and mice with SCD live in an immunologically
altered state. The study presented herein demonstrates that SCD mice are prone to death
associated with vaccination, which is likely linked to the altered baseline immunity observed
in these animals. Consequently, animals that survive inoculation appear to have dysregulated
systemic immune responses to vaccination. Enhanced pulmonary production of IL-1β and
IL-6 suggests acute lung injury may develop as a consequence of antigenic challenge. Our
data suggest that the relative safety and immunogenicity of vaccination should be studied in
greater detail in the context of SCD. Although it is clear that humans with SCD do not suffer
mortality as a consequence of vaccination, there may be subclinical deleterious
consequences that warrant further investigation.
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MATERIALS AND METHODS
Mice
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Animals used in this study have been previously described (8). Briefly, female mice,
approximately 8 weeks old, weighing 15–25 g each, were purchased from the Jackson
Laboratory (Bar Harbor, ME). Berkeley sickle cell transgenic mice (Tg(HuminiLCRα1GγAγδβS) Hba−/− Hbb−/−) expressing human HBA and HBBS and no longer
expressing mouse Hba and Hbb were used as a murine model of SCD. The stock
background of this strain is a mixture of FVB/N, 129, DBA/2, Black Swiss and >50%
C57Bl/6 genomes. It was backcrossed to C57Bl/6 one generation after importation to The
Jackson Laboratory. Hemizygous controls of the Berkeley transgenic SCD mouse (generated
on the same mixed background of strains) that express no mouse Hba, but do express one
copy of mouse Hbb, human HBA and HBBS giving rise to a hemizygous genotype were used
as a second control arm. All mice were conventionally housed in plastic cages with corncob
bedding. The housing facility was maintained at 22–24°C with a 12 hr light/dark cycle.
Chow and water were given ad libitum. The Animal Care Committee at the University of
Connecticut Health Center approved all mouse experiments.
Vaccinations
Mice were vaccinated by either the intraperitoneal (IP) or intramuscular (IM) route once per
week for three weeks. A suspension of 25 μg of OVA (grade V, Sigma Chemical, St. Louis,
MO) with 2 mg of aluminum hydroxide (alum) in 500 μl of saline was used for IP
inoculations, while a final volume of 50 μl was used for IM inoculations (one ½ dose
injection into each hindlimb).
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Collection of Serum and BAL fluid
One week after the third injection, mice were humanely euthanized with an overdose of
ketamine/xylazine and whole blood was immediately collected via cardiac puncture and
placed into non-heparinized tubes for serum purification. Blood was allowed to clot at room
temperature for approximately 30–60 min and then spun for 10 min at 4000 RPM in an
Eppendorf 5415 C centrifuge. Serum was then aliquoted and stored at −80°C until used.
After sacrifice, a bronchoalveolar lavage (BAL) was performed on mouse lungs with five 1ml aliquots of physiologic saline. The BAL was then centrifuged at 1700 × g using a
Thermo Scientific Sorvall ST 40R centrifuge with a swinging bucket rotor and the
supernatant (BAL fluid) was removed and concentrated 10x using Amicon Centriplus
YM-10 filtration devices (Millipore, Bedford, MA), per the manufacturer’s instructions.
BAL fluid samples were stored at −80°C until used.
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Analysis of Cytokines and Antibodies using Luminex Assays
Analysis of serum chemokines/cytokines and antibody class/sub-class were conducted using
Milliplex kits (Millipore), as previously described (8). Cytokines were analyzed using a 1:2
dilution while immunoglobulins were analyzed at a 1:25,000 dilution (concentrations were
adjusted to account for dilution). Serum IgA fell below the detection limit at this dilution for
all animals and was not considered for analysis. BAL fluid cytokines were processed and
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analyzed using the same technique as serum, but sterile PBS was used as a diluent for the
standard curve. For samples in which an analyte could not be detected above the minimum
detection limit (MDL) surrogate values of 0.1 or 1 less than the MDL (depending on the
number of significant figures used) were used. For BAL fluid samples, post-assay sample
concentration and limits of detection were reported taking into consideration the 10X sample
concentration prior to analysis. Fold-change values were calculated using data from naïve
animals published in a previous report (8). Calculations are based on groups of 11 C57Bl/6
mice, 11 hemizygous mice, and 9 SCD mice.
OVA-specific Serum IgE Levels
An OVA-specific sandwich ELISA was used to measure serum levels of IgE, as has been
previously described (29). Results were interpolated from a standard curve. Calculations are
based on groups of 8 C57Bl/6 mice, 9 hemizygous mice, and 8 SCD mice.
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Statistics
Statistical comparisons between groups were made with one-way analysis of variance and
pairwise comparisons were conducted utilizing the Dunnett’s post-hoc test with SCD
serving as the control group. Analyses were conducted using GraphPad Prism version 5
software (GraphPad software, San Diego, CA) unless no variance was recorded within a
group, then JMP statistical software version 5.1 (SAS Institute, Cary, NC) was used. All
data were expressed as means +/− standard error of the mean. Differences were considered
significant if p ≤ 0.05.
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Figure 1.
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Post-vaccination Kaplan-Meier survival curves. (A) Percent survival of C57Bl/6 (n=11),
hemizygous (n=11), or SCD mice (n=15) after each IP vaccination. (B) Percent survival of
C57Bl/6 (n=6), hemizygous (n=7), or SCD mice (n=6) after each IM vaccination. Curves for
SCD mice for both routes of inoculation were significantly different from C57Bl/6 and
hemizyous mice (p<0.05). Squares = C57Bl6 and hemizygous mice; triangle = SCD.
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Figure 2.
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Serum antibody responses to vaccination. (A) Significantly different serum immunoglobulin
concentrations post-vaccination as measured by Luminex assay (IgG2b: C57Bl/6 =
3.88×106 ng/ml (SEM, 2,072,000), hemizygous = 350,000 ng/ml (SEM, 92,000), SCD =
635,000 ng/ml (SEM, 162,000); p<0.01) (IgM: C57Bl/6 = 1.44×106 ng/ml (SEM, 244,000),
hemizygous = 497,000 ng/ml (SEM, 59,000), SCD = 570,000 ng/ml (SEM, 75,000);
p<0.001). (B) Pre- versus postvaccination fold-change in significantly different serum
immunoglobulins postvaccination. (C) Serum concentrations of OVA-specific IgE
antibodies as measured by ELISA (C57Bl/6 = 242 ng/ml (SEM, 48), hemizygous = 1854
ng/ml (SEM, 758), SCD = 2452 ng/ml (SEM, 754); p<0.05). Bars represent mean levels +/−
standard error of the mean. Significant differences were determined by one-way analysis of
variance and pairwise comparisons were conducted using the Dunnett’s post-hoc test with
SCD serving as the control group. Black bars = C57Bl/6; grey bars = hemizygous; white
bars = SCD. *p<0.05, **p<0.01.
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Serum cytokine and chemokine responses to vaccination. (A) Significantly different
postvaccination cytokine/chemokine serum concentrations as measured by Luminex assay
(IL-1α: C57Bl/6 = 2692 pg/ml (SEM, 659), hemizygous = 1224 pg/ml (SEM, 236), SCD =
195 pg/ml (SEM, 64); p<0.001) (IL-2: C57Bl/6 = 55 pg/ml (SEM, 28), hemizygous = 4.2
pg/ml (SEM, 1.4), SCD = 5.8 pg/ml (SEM, 3.2); p<0.05) (IL-5: C57Bl/6 = 54 (SEM, 8.7),
hemizygous = 31 pg/ml (SEM, 5.8), SCD = 27 pg/ml (SEM, 5.2); p<0.05) (MIP-1α:
C57Bl/6 = 53 pg/ml (SEM, 16), hemizygous = 15 pg/ml (SEM, 4.9), SCD = 19 pg/ml (SEM,
8.8); p<0.05) (GM-CSF: C57Bl/6 = 89 pg/ml (SEM, 31), hemizygous = 5.5 pg/ml (SEM,
NA), SCD = 10 pg/ml (SEM, 4.7); p<0.01). (B) Pre- versus post-vaccination fold-change in
significantly different post-vaccination serum cytokines/chemokines. (C) Fold-change in
serum cytokines that were only significantly different pre- versus post-vaccination in
C57Bl/6 mice. Bars represent mean levels +/− standard error of the mean. Significant
differences were determined by one-way analysis of variance and pairwise comparisons
were conducted using the Dunnett’s post-hoc test with SCD serving as the control group.
Black bars = C57Bl/6; grey bars = hemizygous; white bars = SCD. *p<0.05, **p<0.01.
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Figure 4.
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BAL fluid cytokines measured in response to vaccination. No cytokines were detected above
the MDL before vaccination (IL-1β: C57Bl/6 < 0.20 pg/ml, hemizygous = 1.8 pg/ml (SEM,
1.1), SCD = 11 pg/ml (SEM, 4.9); p<0.05) (IL-6: C57Bl/6 < 0.28 pg/ml, hemizygous = 6.5
pg/ml (SEM, 3.5), SCD = 17 pg/l (SEM, 5.9); p<0.05). Bars represent mean levels +/−
standard error of the mean. Significant differences were determined by one-way analysis of
variance and pairwise comparisons were conducted utilizing the Dunnett’s post-hoc test with
SCD serving as the control group. Black bars = C57Bl/6; grey bars = hemizygous; white
bars = SCD. *p<0.05
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